Thomas G. Wiggans Sells 11,000 Shares of Dermira Inc. (DERM) Stock
Dermira Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 11,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $34.60, for a total transaction of $380,600.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Dermira Inc. (NASDAQ:DERM) opened at 34.77 on Wednesday. The stock has a 50 day moving average of $33.01 and a 200-day moving average of $29.42. Dermira Inc. has a one year low of $17.42 and a one year high of $36.16. The stock’s market capitalization is $1.23 billion.
Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. Equities analysts forecast that Dermira Inc. will post ($3.39) earnings per share for the current year.
Several institutional investors have recently modified their holdings of the stock. TimesSquare Capital Management LLC increased its stake in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock valued at $72,877,000 after buying an additional 1,101,645 shares during the last quarter. FMR LLC increased its stake in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock valued at $118,847,000 after buying an additional 921,800 shares during the last quarter. Jennison Associates LLC increased its stake in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock valued at $73,539,000 after buying an additional 860,597 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in Dermira during the second quarter valued at approximately $10,678,000. Finally, Vanguard Group Inc. increased its stake in Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock valued at $27,529,000 after buying an additional 304,750 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.
DERM has been the topic of several recent research reports. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, June 14th. Needham & Company LLC reaffirmed a “positive” rating and set a $46.00 price objective on shares of Dermira in a report on Monday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $41.00.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.